Secarna Pharmaceuticals enters into discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target
- The companies will jointly develop a first-in-class disease-modifying oligonucleotide against a newly validated target relevant for rare genetic disorders as well as broader disease conditions
- Collaboration will leverage expertise and synergies of both companies’ platforms to bring new treatments to patients
Martinsried (Munich), Germany, October 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the signing of an agreement with Scenic Biotech B.V., a pioneer in modifier therapies for severe genetic diseases. The agreement covers the discovery and co-development of oligonucleotides against a novel target identified and validated by Scenic Biotech’s proprietary Cell-Seq platform.
Secarna will lead the oligonucleotide discovery part of the collaboration, bringing OligoCreator®, its proprietary AI-empowered oligonucleotide discovery and development platform, to the co-development. OligoCreator® has been shown to greatly expedite the drug discovery process, from target selection to therapeutic development, identifying and characterizing potentially safe and efficacious therapeutic candidates at unparalleled speed. Within the collaboration, Secarna will utilize its platform to identify promising candidates, while Scenic will add its expertise on target and disease biology.
Secarna Pharmaceuticals and VERAXA Biotech Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
- Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases
Martinsried (Munich), Germany, and Zurich, Switzerland, September 30, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.(NASDAQ:VACH, “Voyager”), today announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs). The combination of both technology platforms aims to unlock novel targeted therapies for the treatment of autoimmune and chronic immune diseases.
Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
- The partnership combines Secarna’s OligoCreator® technology with Vect-Horus’ VECTrans® platform to enable systemic delivery of oligonucleotide therapies across the blood-brain barrier
- This collaboration marks a strategic step for both companies in expanding their presence in targeted delivery and CNS indications, uniting complementary expertise in RNA therapeutics and advanced delivery technologies
- This strategic agreement unlocks new potential treatments for neurodegenerative and other CNS disorders and delivering solutions that truly impact patient lives
Martinsried, Germany, and Marseille, France, July 10, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and Vect-Horus, an expert in the design and development of molecular vectors to facilitate targeted delivery of therapeutic molecules and imaging agents, today announced that the companies have entered into a strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS).
Would you like to keep up to date with the latest from Secarna Pharmaceuticals?
Click here to subscribe here to receive regular updates:
Latest News & Events
Secarna Pharmaceuticals enters into discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target
- The companies will jointly develop a first-in-class disease-modifying oligonucleotide against a newly validated target relevant for rare genetic disorders as well as broader disease conditions
- Collaboration will leverage expertise and synergies of both companies’ platforms to bring new treatments to patients
Martinsried (Munich), Germany, October 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the signing of an agreement with Scenic Biotech B.V., a pioneer in modifier therapies for severe genetic diseases. The agreement covers the discovery and co-development of oligonucleotides against a novel target identified and validated by Scenic Biotech’s proprietary Cell-Seq platform.
Secarna will lead the oligonucleotide discovery part of the collaboration, bringing OligoCreator®, its proprietary AI-empowered oligonucleotide discovery and development platform, to the co-development. OligoCreator® has been shown to greatly expedite the drug discovery process, from target selection to therapeutic development, identifying and characterizing potentially safe and efficacious therapeutic candidates at unparalleled speed. Within the collaboration, Secarna will utilize its platform to identify promising candidates, while Scenic will add its expertise on target and disease biology.
Secarna Pharmaceuticals and VERAXA Biotech Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
- Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases
Martinsried (Munich), Germany, and Zurich, Switzerland, September 30, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.(NASDAQ:VACH, “Voyager”), today announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs). The combination of both technology platforms aims to unlock novel targeted therapies for the treatment of autoimmune and chronic immune diseases.
Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
- The partnership combines Secarna’s OligoCreator® technology with Vect-Horus’ VECTrans® platform to enable systemic delivery of oligonucleotide therapies across the blood-brain barrier
- This collaboration marks a strategic step for both companies in expanding their presence in targeted delivery and CNS indications, uniting complementary expertise in RNA therapeutics and advanced delivery technologies
- This strategic agreement unlocks new potential treatments for neurodegenerative and other CNS disorders and delivering solutions that truly impact patient lives
Martinsried, Germany, and Marseille, France, July 10, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and Vect-Horus, an expert in the design and development of molecular vectors to facilitate targeted delivery of therapeutic molecules and imaging agents, today announced that the companies have entered into a strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS).